Targeted Therapies for Cancer: ImmunoGen, Inc.

Site Map

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Data presentations on several TAP compounds will be made in early December

See a list of these presentations

Lead compound with TAP technology, T-DM1, showed efficacy, tolerability advantages in Phase II trial.

View the presentation here...

1/30/2012
ImmunoGen, Inc. Announces Addition of Kristine Peterson and Dean Mitchell to Its Board of Directors

1/27/2012
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update

1/18/2012
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2012 Financial Results

Read our releases...

built@zoomedia.com

Last updated January 27, 2012